Celiac disease-related autoantibodies in end-stage autoimmune liver diseases: what is the message?

Hepatocellular carcinoma (HCC), the commonest among liver cancers, is one of the leading causes of mortality among malignancies worldwide. Several reports demonstrate autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) to confer increased risk of hepatobiliary malignancies, albeit at lower frequencies compared to other liver diseases. Several parameters have been recognized as risk factors for HCC development in AIH and PBC, including demographics such as older age and male sex, clinical features, the most decisive being cirrhosis and other co-existing factors, such as alcohol consumption. Moreover, biochemical activity and treatment response have been increasingly recognized as prognostic factors for HCC development in AIH and PBC. As available treatment modalities are effective only when HCC diagnosis is established early, surveillance has been proven essential for HCC prognosis. Considering that the risk for HCC is not uniform between and within disease groups, refinement of screening strategies according to prevailing demographic, clinical, and molecular risk factors is mandated in AILDs patients, as personalized HCC risk prediction will offer significant advantage in patients at high and/or medium risk. Furthermore, future investigations should draw attention to whether modification of immunosuppression could benefit AIH patients after HCC diagnosis.

Download Full-text

Pretransplant Prediction of Posttransplant Survival for Liver Recipients with Benign End-Stage Liver Diseases: A Nonlinear Model

PLoS ONE ◽

10.1371/journal.pone.0031256 ◽

2012 ◽

Vol 7 (3) ◽

pp. e31256 ◽

Cited By ~ 19

Author(s):

Ming Zhang ◽

Fei Yin ◽

Bo Chen ◽

You Ping Li ◽

Lu Nan Yan ◽

...

Keyword(s):

Nonlinear Model ◽

Liver Diseases ◽

End Stage

Download Full-text

Histological recurrence of autoimmune liver diseases after living-donor liver transplantation

Hepatology Research ◽

10.1111/j.1872-034x.2007.00245.x ◽

2007 ◽

Vol 37 (s3) ◽

pp. S463-S469 ◽

Cited By ~ 35

Author(s):

Hironori Haga ◽

Aya Miyagawa-Hayashino ◽

Kaoru Taira ◽

Daisuke Morioka ◽

Hiroto Egawa ◽

...

Keyword(s):

Liver Transplantation ◽

Liver Diseases ◽

Living Donor ◽

Living Donor Liver Transplantation ◽

Donor Liver ◽

Donor Liver Transplantation ◽

Autoimmune Liver Diseases

Download Full-text

Elevated platelet distribution width and red cell distribution width are associated with autoimmune liver diseases

European Journal of Gastroenterology & Hepatology ◽

10.1097/meg.0000000000002296 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Muge Ustaoglu ◽

Gulali Aktas ◽

Ufuk Avcioglu ◽

Berk Bas ◽

Bugra Kaan Bahceci

Keyword(s):

Liver Diseases ◽

Red Cell Distribution Width ◽

Red Cell ◽

Cell Distribution ◽

Platelet Distribution Width ◽

Distribution Width ◽

Autoimmune Liver Diseases

Download Full-text

Three-dimensional Printing-Driving Liver Therapies

Current Medicinal Chemistry ◽

10.2174/0929867328666210419124246 ◽

2021 ◽

Vol 28 ◽

Author(s):

Xiaohong Li ◽

Liang Wen ◽

Jiao Liu ◽

Xiaohong Wang

Keyword(s):

Liver Diseases ◽

Effective Means ◽

Three Dimensional ◽

3D Bioprinting ◽

Three Dimensional Printing ◽

Bottle Neck ◽

Magnetic Resonance Imaging Mri ◽

End Stage ◽

Bioartificial Livers ◽

Dimensional Printing

: End-stage liver diseases have long been a threat to human health, and so far, the treatment of these diseases lacks of effective means. Allogenic organ transplantation has become the last straw for most of the patients with end-stage liver diseases. However, this technique has been greatly limited by the serious shortage of donors and other factors, such as immune rejection, drug syndrome, and high cost. Recently, the emergence of three-dimensional (3D) bioprinting technologies, together with the magnetic resonance imaging (MRI) and computed tomography (CT) techniques, has driven the rapid growth of this field toward liver therapies. There are several basic requirements for liver 3D bioprinting. From information collection of diseased livers, to 3D printing of liver substitutes (containing the major structural, material and functional characters), and to clinical applications, suitable ‘bioinks’ and ‘bioprinters’ have played essential roles. In this review, we highlight the advanced ‘bioinks’ and ‘bioprinters’ that have been used for vascularized and innervated liver tissue 3D bioprinting. Further studies for the incorporation of biliary networks in the bioartificial livers have been emphasized. It is expected that when all the bottle-neck problems for liver 3D bioprinting are solved, batch (i.e. mass) and personalized production of bioartificial livers will make it very easy to treat end-stage liver diseases.

Download Full-text

The Association of Two Rare Diseases is Not Rare: Primary Immunodeficiencies and Autoimmune Liver Diseases

10.21203/rs.3.rs-748416/v1 ◽

2021 ◽

Author(s):

Şefika Nur Ayar ◽

Elif Soyak ◽

Cem Şimşek ◽

Deniz Çağdaş ◽

Yasemin Balaban

Keyword(s):

Rare Diseases ◽

Liver Diseases ◽

Strong Association ◽

Laboratory Data ◽

Tertiary Hospital ◽

Iga Deficiency ◽

Primary Biliary Cholangitis ◽

Cross Sectional ◽

Autoimmune Liver Diseases ◽

Igm Deficiency

Abstract Purpose: PIDs associates with autoimmune diseases include autoimmune liver diseases (AILD); however, the frequency of PIDs among patients with AILD is unknown. This study aimed to evaluate the strength of the association between AILD and PIDs. Methods: We conducted this single-center, cross-sectional, and descriptive study in a tertiary hospital. We evaluated eighty-two patients with AILD (39 autoimmune hepatitis (AIH), 32 with primary biliary cholangitis (PBC), seven with variant syndromes (VS), and four with primary sclerosing cholangitis (PSC) for the presence of PIDs. We obtained a detailed history of infections, comorbidities, family history, and laboratory data from the files. All patients were evaluated in the immunology department for further examination, and PID diagnoses were made according to ESID (The European Society for Immunodeficiencies) criteria. Results: Out of 82 patients with AILD, PIDs were diagnosed in 18% (15 patients); there were four patients with common variable immunodeficiency (CVID), four with partial IgA deficiency (PIgAD), four with selective IgM deficiency (SIgMD), and three with combined immunodeficiency (CID). PIDs were present in 29% of patients with VS, 25 % of patients with PSC, 23% of patients with AIH, and 9% of patients with PBC. Conclusion: Although PIDs are rare diseases in the general population, they have a strong association with AILD and were detected in one-fifth of the patients. Further research with larger patient groups is needed to evaluate the diagnostic and prognostic impacts of PIDs on AILD.

Download Full-text